Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.33 |
| ▸ | POLB | P06746 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.31 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.31 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6833631 | 1.00 | TDP1 (0.33) | TDP1POLBMAPTTPSAB1TPSD1 | |
| Imidazole SCHEMBL4579994 | 0.92 | — | — | |
| SCHEMBL9320151 | 0.88 | TPSAB1 (0.43) | TDP1POLBMAPTTPSAB1TPSD1 | |
| SCHEMBL8189733 | 0.88 | TDP1 (0.34) | TDP1POLBMAPTNPSR1ATM | |
| SCHEMBL26923344 | 0.87 | HTR2C (0.34) | MAPT | |
| SCHEMBL29683397 | 0.87 | HTR2C (0.34) | MAPT | |
| SCHEMBL29520467 | 0.85 | MMP13 (0.32) | TDP1POLBMAPT | |
| SCHEMBL2133987 | 0.83 | MDM2 (0.38) | TPSAB1TPSD1TPSG1 | |
| SCHEMBL22610140 | 0.83 | MDM2 (0.38) | TPSAB1TPSD1TPSG1 | |
| SCHEMBL7267095 | 0.83 | POLB (0.45) | TDP1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| EP-4534524-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PeptiDream Inc. (JP) | 2025-04-09 | — | — | EP | disclosed |
| CN-118930602-A | Method for performing terminal allylation modification on natural amino acid or polypeptide | 南京工业大学 | 2024-11-12 | — | — | CN | disclosed |
| CN-118725014-A | Mitochondrial targeting peptides | 隐形生物治疗公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-118702767-A | Mitochondrial targeting peptides | 隐形生物治疗公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-118702766-A | Mitochondrial targeting peptides | 隐形生物治疗公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-111954539-B | Mitochondrial targeting peptides | 隐形生物治疗公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20240059734-A1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2024-02-22 | — | — | US | disclosed |
| WO-2023236573-A1 | METHOD FOR PREPARING HIGH-SPECIFIC-VOLUME LOW-VOLTAGE ELECTRODE FOIL FOR AUTOMOTIVE ELECTRONICS | 南通海星电子股份有限公司 | 2023-12-14 | — | — | WO | disclosed |
| US-11795196-B2 | Mitochondria-targeting peptides | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20030077334-A1 | Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanism for normal and transformed cells | KOZHEMYAKIN LEONID A (RU) | 2003-04-24 | — | — | US | disclosed |
| EP-0873123-B1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIV PITTSBURGH (US) | 2003-04-09 | — | — | EP | disclosed |
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | UNIVERSITY OF PITTSBURGH (US) | 2002-12-19 | — | — | US | disclosed |
| US-20020016288-A1 | Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells | KOZHEMYAKIN LEONID A (RU) | 2002-02-07 | — | — | US | disclosed |
| US-6312734-B1 | FORMING AN OXIDIZED GLUTATIONE COMPLEX WITH PLATINUM OR PALLADIUM | NOVELOS THERAPEUTICS, INC. | 2001-11-06 | — | — | US | disclosed |
| EP-1131340-A2 | HEXAPEPTIDE WITH THE STABILIZED DISULFIDE BOND AND DERIVATIVES THEREOF REGULATING METABOLISM, PROLIFERATION, DIFFERENTIATION AND APOPTOSIS | Novelos Therapeutics, Inc. (US) | 2001-09-12 | — | — | EP | disclosed |
| WO-2000031120-A2 | HEXAPEPTIDE WITH THE STABILIZED DISULFIDE BOND AND DERIVATIVES THEREOF REGULATING METABOLISM, PROLIFERATION, DIFFERENTIATION AND APOPTOSIS | NOVELOS THERAPEUTICS, INC. (US) | 2000-06-02 | — | — | WO | disclosed |
| US-4859654-A | Homocyclostatine and cyclostatine containing polypeptides as antihypertensive agents | PFIZER INC. (US) | 1989-08-22 | — | — | US | disclosed |
| US-4818748-A | HYPOTENSIVE AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1989-04-04 | — | — | US | disclosed |
| EP-0236874-A2 | Renin inhibitors, their production and use, as well as derivatives of amino acids and amino aldehydes | BAYER AG (DE) | 1987-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | LANCL1, FNTB, DHCR7 | TDP1 3740/4885POLB 2803/4885MAPT 4674/4885 |
| US-20020016288-A1 | Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells | GPX4, GPX1, GSR | TDP1 3397/4885POLB 671/4885MAPT 3853/4885 |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | TDP1 720/4885POLB 948/4885MAPT 4146/4885 |
| US-20030077334-A1 | Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanism for normal and transformed cells | GPX4, GPX1, GSR | TDP1 3407/4885POLB 694/4885MAPT 3830/4885 |
| US-11795196-B2 | Mitochondria-targeting peptides | HSPE1, TFAM, TNNI3 | TDP1 2124/4885POLB 1250/4885MAPT 4363/4885 |
| US-20240059734-A1 | MITOCHONDRIA-TARGETING PEPTIDES | HSPE1, TFAM, TNNI3 | TDP1 2124/4885POLB 1250/4885MAPT 4363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.